成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

Home Cart 0 Sign in  

[ CAS No. 842133-18-0 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
Chemical Structure| 842133-18-0
Chemical Structure| 842133-18-0
Structure of 842133-18-0 * Storage: {[proInfo.prStorage]}

Please Login or Create an Account to: See VIP prices and availability

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

* Shipping: {[proInfo.prShipping]}

Quality Control of [ 842133-18-0 ]

Related Doc. of [ 842133-18-0 ]

Alternatived Products of [ 842133-18-0 ]
Product Citations

Product Citations

Hasan, Ahasanul ; Zerin, Farzana ; Menon, Sreelakshmi N , et al. DOI: PubMed ID:

Abstract: Canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, is reported to produce beneficial cardiovascular effects including a reduction in arterial contractility, and blood pressure. However, whether canagliflozin could directly relax resistance mesenteric arteries, underlying molecular mechanism and its role in regulating systemic blood pressure remain unclear. Here, we investigated the mechanism of regulation of small mesenteric artery contractility and its relevance for blood pressure regulation. Our pressure myography data showed that canagliflozin application rapidly produces a concentration-dependent vasodilation in mesenteric arteries. Such vasodilation was inhibited by concurrent inhibition of smooth muscle cell voltage-gated Kt channels KV1.5 (by 1 mM DPO-1), KV2.1 (by 100 nM guangxitoxin), and KV7 (by 10 mM linopirdine) but not by the inhibition of small-, intermediate-, and large-conductance Ca2t-activated Kt channels (SKCa by 1 mM apamin, IKCa 10 mM TRAM-34, and BKCa by 10 mM paxilline, respectively), ATP-sensitive (KATP) channels (by 10 mM glibenclamide), or SERCA pump (by 0.1 mM thapsigargin). Inhibition of SGLTs (by 1 mM phlorizin or the inhibition of endothelial signaling did not alter canagliflozin-evoked vasodilation. Consistently, acute canagliflozin treatment (4 mg/kg body weight) lowered systemic blood pressure in vivo. Overall, our data suggests that canagliflozin stimulates KV1.5, KV2.1, and KV7 channels, leading to vasodilation and a reduction of systemic blood pressure.

Keywords: Canagliflozin ; Mesenteric arteries ; Voltage-gated Kt channels ; Vasorelaxation ; Blood pressure

Purchased from AmBeed:

Product Details of [ 842133-18-0 ]

CAS No. :842133-18-0 MDL No. :MFCD18251436
Formula : C24H25FO5S Boiling Point : -
Linear Structure Formula :- InChI Key :XTNGUQKDFGDXSJ-ZXGKGEBGSA-N
M.W : 444.52 Pubchem ID :24812758
Synonyms :
JNJ 28431754;TA-7284;JNJ-24831754
Chemical Name :(2S,3R,4R,5S,6R)-2-(3-((5-(4-Fluorophenyl)thiophen-2-yl)methyl)-4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol

Safety of [ 842133-18-0 ]

Signal Word:Danger Class:N/A
Precautionary Statements:P201-P202-P280-P281-P305+P351+P338-P308+P313-P310-P405-P501 UN#:N/A
Hazard Statements:H318-H361 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 842133-18-0 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 842133-18-0 ]
Recommend Products
Same Skeleton Products

Technical Information

Historical Records
; ;